I-08 Teijo Saari Pharmacokinetics of free hydromorphone concentrations in patients after cardiac surgery Wednesday 10:05-11:40 |
I-23 Christine Staatz Dosage individulisation of tacroliums in adult kidney transplant recipients Wednesday 10:05-11:40 |
I-24 Gabriel Stillemans A generic population pharmacokinetic model for tacrolimus in pediatric and adult kidney and liver allograft recipients Wednesday 10:05-11:40 |
I-32 Amit Taneja From Behaviour to Target: Evaluating the putative correlation between clinical pain scales and biomarkers. Wednesday 10:05-11:40 |
I-34 David Ternant Adalimumab pharmacokinetics and concentration-effect relationship in rheumatoid arthritis Wednesday 10:05-11:40 |
I-45 Marc Vandemeulebroecke Literature databases: integrating information on diseases and their treatments. Wednesday 10:05-11:40 |
I-47 An Vermeulen Population Pharmacokinetic Analysis of Canagliflozin, an Orally Active Inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) Wednesday 10:05-11:40 |
I-48 Marie Vigan Modelling the evolution of two biomarkers in Gaucher patients receiving enzyme replacement therapy. Wednesday 10:05-11:40 |
I-54 Bing Wang Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and asthma patients Wednesday 10:05-11:40 |
I-56 Franziska Weber A linear mixed effect model describing the expression of peroxisomal ABCD transporters in CD34+ stem cell-derived immune cells of X-linked Adrenoleukodystrophy and control populations Wednesday 10:05-11:40 |
I-57 Sebastian Weber PK/PD assessment of tacrolimus nephrotoxicity in liver transplantation Wednesday 10:05-11:40 |
I-59 Dan Wright Bayesian dose individualisation provides good control of warfarin dosing. Wednesday 10:05-11:40 |
I-62 Shuying Yang First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis Wednesday 10:05-11:40 |
I-64 Rui Zhu Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy Wednesday 10:05-11:40 |
II-16 Aurelie Gautier Pharmacokinetics of Canakinumab and pharmacodynamics of IL-1β binding in cryopyrin associated periodic fever, a step towards personalized medicine Wednesday 14:50-16:20 |
II-25 Sophie Gisbert Is it possible to use the plasma and urine pharmacokinetics of a monoclonal antibody (mAb) as an early marker of efficacy in membranous nephropathy (MN)? Wednesday 14:50-16:20 |
II-51 Jeremie Guedj Modeling Early Viral Kinetics with Alisporivir: Interferon-free Treatment and SVR Predictions in HCV G2/3 patients Wednesday 14:50-16:20 |
II-52 Claire Johnston A population approach to investigating hepatic intrinsic clearance in old age: Pharmacokinetics of paracetamol and its metabolites Wednesday 14:50-16:20 |
II-57 Ana Novakovic Application of Item Response Theory to EDSS Modeling in Multiple Sclerosis Wednesday 14:50-16:20 |
III-05 Cédric Laouenan Modelling early viral hepatitis C kinetics in compensated cirrhotic treatment-experienced patients treated with triple therapy including telaprevir or boceprevir Thursday 10:05-11:35 |
III-08 Donghwan Lee Development of a Disease Progression Model in Korean Patients with Type 2 Diabetes Mellitus(T2DM) Thursday 10:05-11:35 |
III-09 Joomi Lee Population pharmacokinetics of prothionamide in Korean tuberculosis patients Thursday 10:05-11:35 |
III-11 Tarek Leil PK-PD Modeling using 4β-Hydroxycholesterol to Predict CYP3A Mediated Drug Interactions Thursday 10:05-11:35 |
III-12 Annabelle Lemenuel Diot How to improve the prediction of Sustained Virologic Response (SVR) for Hepatitis C patients using early Viral Load (VL) Information Thursday 10:05-11:35 |
III-21 Dan Lu Semi-mechanistic Multiple-analyte Population Model of Antibody-drug-conjugate Pharmacokinetics Thursday 10:05-11:35 |
III-36 Enrica Mezzalana A Target-Mediated Drug Disposition model integrated with a T lymphocyte pharmacodynamic model for Otelixizumab. Thursday 10:05-11:35 |
III-40 John Mondick Mixed Effects Modeling to Quantify the Effect of Empagliflozin Exposure on the Renal Glucose Threshold in Patients with Type 2 Diabetes Mellitus Thursday 10:05-11:35 |
III-41 Morris Muliaditan Model-based evaluation of iron overload in patients affected by transfusion dependent diseases Thursday 10:05-11:35 |
III-42 Flora Musuamba-Tshinanu Modelling of disease progression and drug effects in preclinical models of neuropathic pain Thursday 10:05-11:35 |
III-44 Thu Thuy Nguyen Mechanistic Model to Characterize and Predict Fecal Excretion of Ciprofloxacin Resistant Enterobacteria with Various Dosage Regimens Thursday 10:05-11:35 |
III-50 Jaeseong Oh A Population Pharmacokinetic-Pharmacodynamic Analysis of Fimasartan in Patients with Mild to Moderate Essential Hypertension Thursday 10:05-11:35 |
III-54 Sean Oosterholt PKPD modelling of PGE2 inhibition and dose selection of a novel COX-2 inhibitor in humans. Thursday 10:05-11:35 |
III-56 Jeongki Paek Population pharmacokinetic model of sildenafil describing first-pass effect to its metabolite Thursday 10:05-11:35 |
III-57 Sung Min Park Population pharmacokinetic/pharmacodynamic modeling for transformed binary effect data of triflusal in healthy Korean male volunteers Thursday 10:05-11:35 |
IV-03 Wafa Alfwzan Mathematical Modelling of the Spread of Hepatitis C among Drug Users, effects of heterogeneity. Thursday 14:55-16:20 |
IV-08 Helena Edlund Clinical relevance of albumin concentration in patients with Crohn’s disease treated with infliximab for recommendations on dosing regimen adjustments Thursday 14:55-16:20 |
IV-09 Franc Andreu Solduga Development of a Bayesian Estimator for Tacrolimus in Kidney Transplant Patients: A Population Pharmacokinetic approach. Thursday 14:55-16:20 |
IV-15 Shanshan Bi Population Pharmacokinetic/Pharmacodynamic Modeling of Two Novel Neutral Endopeptidase Inhibitors in Healthy Subjects Thursday 14:55-16:20 |
IV-17 Roberto Bizzotto Characterization of binding between OSM and mAb in RA patient study: an extension to TMDD models Thursday 14:55-16:20 |
IV-19 Karina Blei Mechanism of Action of Jellyfish (Carukia barnesi) Envenomation and its Cardiovascular Effects Resulting in Irukandji Syndrome Thursday 14:55-16:20 |
IV-20 Michael Block Predicting the antihypertensive effect of Candesartan-Nifedipine combinations based on public benchmarking data. Thursday 14:55-16:20 |
IV-21 Michael Block Physiologically-based PK/PD modeling for a dynamic cardiovascular system: structure and applications Thursday 14:55-16:20 |
IV-36 Kalayanee Chairat A population pharmacokinetics and pharmacodynamics of oseltamivir and oseltamivir carboxylate in adults and children infected with influenza virus A(H1N1)pdm09 Thursday 14:55-16:20 |
IV-41 Chao Chen A mechanistic model for the involvement of the neonatal Fc receptor in IgG disposition Thursday 14:55-16:20 |
IV-42 Chunli Chen Design optimization for characterization of rifampicin pharmacokinetics in mouse Thursday 14:55-16:20 |
IV-58 Willem de Winter Population PK/PD analysis linking the direct acute effects of canagliflozin on renal glucose reabsorption to the overall effects of canagliflozin on long-term glucose control using HbA1c as the response marker from clinical studies Thursday 14:55-16:20 |
IV-59 Joost DeJongh A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. Thursday 14:55-16:20 |
IV-60 Paolo Denti A semi-physiological model for rifampicin and rifapentine CYP3A induction on midazolam pharmacokinetics. Thursday 14:55-16:20 |